#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Pancreatic cancer ( PC ) is the one of the most aggressive and therapeutically ineffective malignant cancers .
3-1	17-27	Pancreatic	place|abstract[4]	new|new[4]	coref|coref	4-10[0_4]|4-10[0_4]
3-2	28-34	cancer	abstract[4]	new[4]	_	_
3-3	35-36	(	_	_	_	_
3-4	37-39	PC	object	new	coref	4-4
3-5	40-41	)	_	_	_	_
3-6	42-44	is	_	_	_	_
3-7	45-48	the	abstract[6]	new[6]	_	_
3-8	49-52	one	abstract[6]	new[6]	_	_
3-9	53-55	of	abstract[6]	new[6]	_	_
3-10	56-59	the	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-11	60-64	most	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-12	65-75	aggressive	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-13	76-79	and	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-14	80-95	therapeutically	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-15	96-107	ineffective	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-16	108-117	malignant	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-17	118-125	cancers	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-18	126-127	.	_	_	_	_

#Text=Mortality due to PC is fourth among the various cancer types worldwide .
4-1	128-137	Mortality	abstract[8]	new[8]	coref	6-7[18_8]
4-2	138-141	due	abstract[8]	new[8]	_	_
4-3	142-144	to	_	_	_	_
4-4	145-147	PC	abstract	giv	coref	5-11
4-5	148-150	is	_	_	_	_
4-6	151-157	fourth	_	_	_	_
4-7	158-163	among	_	_	_	_
4-8	164-167	the	abstract[11]	new[11]	_	_
4-9	168-175	various	abstract[11]	new[11]	_	_
4-10	176-182	cancer	abstract|abstract[11]	giv|new[11]	coref	8-27
4-11	183-188	types	abstract[11]	new[11]	_	_
4-12	189-198	worldwide	abstract[11]	new[11]	_	_
4-13	199-200	.	_	_	_	_

#Text=In 2018 , 458,918 new cases and 432,242 deaths by PC were recorded worldwide .
5-1	201-203	In	_	_	_	_
5-2	204-208	2018	time	new	_	_
5-3	209-210	,	_	_	_	_
5-4	211-218	458,918	abstract[13]	new[13]	_	_
5-5	219-222	new	abstract[13]	new[13]	_	_
5-6	223-228	cases	abstract[13]	new[13]	_	_
5-7	229-232	and	_	_	_	_
5-8	233-240	432,242	event[14]	new[14]	coref	8-27[45_14]
5-9	241-247	deaths	event[14]	new[14]	_	_
5-10	248-250	by	event[14]	new[14]	_	_
5-11	251-253	PC	event[14]|object	new[14]|giv	coref	7-6
5-12	254-258	were	_	_	_	_
5-13	259-267	recorded	_	_	_	_
5-14	268-277	worldwide	_	_	_	_
5-15	278-279	.	_	_	_	_

#Text=One of the primary reasons for the high mortality is the difficulty in early diagnosis of the disease because pancreas is behind the stomach and the patient shows general symptoms such as digestive problems , abdominal pain , and weight loss before metastasis .
6-1	280-283	One	abstract[16]	new[16]	coref	6-11[19_16]
6-2	284-286	of	abstract[16]	new[16]	_	_
6-3	287-290	the	abstract[16]|abstract[17]	new[16]|new[17]	_	_
6-4	291-298	primary	abstract[16]|abstract[17]	new[16]|new[17]	_	_
6-5	299-306	reasons	abstract[16]|abstract[17]	new[16]|new[17]	_	_
6-6	307-310	for	abstract[16]|abstract[17]	new[16]|new[17]	_	_
6-7	311-314	the	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|giv[18]	_	_
6-8	315-319	high	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|giv[18]	_	_
6-9	320-329	mortality	abstract[16]|abstract[17]|abstract[18]	new[16]|new[17]|giv[18]	_	_
6-10	330-332	is	_	_	_	_
6-11	333-336	the	abstract[19]	giv[19]	_	_
6-12	337-347	difficulty	abstract[19]	giv[19]	_	_
6-13	348-350	in	abstract[19]	giv[19]	_	_
6-14	351-356	early	abstract[19]|event[20]	giv[19]|new[20]	coref	7-14[0_20]
6-15	357-366	diagnosis	abstract[19]|event[20]	giv[19]|new[20]	_	_
6-16	367-369	of	abstract[19]|event[20]	giv[19]|new[20]	_	_
6-17	370-373	the	abstract[19]|event[20]|abstract[21]	giv[19]|new[20]|new[21]	_	_
6-18	374-381	disease	abstract[19]|event[20]|abstract[21]	giv[19]|new[20]|new[21]	_	_
6-19	382-389	because	_	_	_	_
6-20	390-398	pancreas	object	new	_	_
6-21	399-401	is	_	_	_	_
6-22	402-408	behind	_	_	_	_
6-23	409-412	the	place[23]	new[23]	_	_
6-24	413-420	stomach	place[23]	new[23]	_	_
6-25	421-424	and	_	_	_	_
6-26	425-428	the	person[24]	new[24]	_	_
6-27	429-436	patient	person[24]	new[24]	_	_
6-28	437-442	shows	_	_	_	_
6-29	443-450	general	abstract[25]	new[25]	_	_
6-30	451-459	symptoms	abstract[25]	new[25]	_	_
6-31	460-464	such	abstract[25]	new[25]	_	_
6-32	465-467	as	abstract[25]	new[25]	_	_
6-33	468-477	digestive	abstract[25]|abstract|abstract[27]	new[25]|new|new[27]	coref|coref	18-24[131_27]|18-24[131_27]
6-34	478-486	problems	abstract[25]|abstract[27]	new[25]|new[27]	_	_
6-35	487-488	,	abstract[25]	new[25]	_	_
6-36	489-498	abdominal	abstract[25]|abstract[28]	new[25]|new[28]	_	_
6-37	499-503	pain	abstract[25]|abstract[28]	new[25]|new[28]	_	_
6-38	504-505	,	abstract[25]	new[25]	_	_
6-39	506-509	and	abstract[25]	new[25]	_	_
6-40	510-516	weight	abstract[25]|place|abstract[30]	new[25]|new|new[30]	coref|coref	13-22[92_30]|13-22[92_30]
6-41	517-521	loss	abstract[25]|abstract[30]	new[25]|new[30]	_	_
6-42	522-528	before	abstract[25]|abstract[30]	new[25]|new[30]	_	_
6-43	529-539	metastasis	abstract[25]|abstract[30]|abstract	new[25]|new[30]|new	coref	7-9
6-44	540-541	.	_	_	_	_

#Text=More than 80 % of PC patients show metastasis at the time of diagnosis .
7-1	542-546	More	_	_	_	_
7-2	547-551	than	_	_	_	_
7-3	552-554	80	quantity[32]	new[32]	_	_
7-4	555-556	%	quantity[32]	new[32]	_	_
7-5	557-559	of	quantity[32]	new[32]	_	_
7-6	560-562	PC	quantity[32]|abstract|person[34]	new[32]|giv|new[34]	coref|coref|coref|coref	8-11|10-9[55_34]|8-11|10-9[55_34]
7-7	563-571	patients	quantity[32]|person[34]	new[32]|new[34]	_	_
7-8	572-576	show	_	_	_	_
7-9	577-587	metastasis	object	giv	_	_
7-10	588-590	at	_	_	_	_
7-11	591-594	the	_	_	_	_
7-12	595-599	time	_	_	_	_
7-13	600-602	of	_	_	_	_
7-14	603-612	diagnosis	event	giv	_	_
7-15	613-614	.	_	_	_	_

#Text=Despite various therapeutic methods , the 5-year survival rate of PC is only 8 % and PC is projected to be the second leading cause of cancer deaths by 2030 .
8-1	615-622	Despite	_	_	_	_
8-2	623-630	various	abstract[37]	new[37]	_	_
8-3	631-642	therapeutic	abstract[37]	new[37]	_	_
8-4	643-650	methods	abstract[37]	new[37]	_	_
8-5	651-652	,	_	_	_	_
8-6	653-656	the	quantity[39]	new[39]	coref	8-13[41_39]
8-7	657-663	5-year	quantity[39]	new[39]	_	_
8-8	664-672	survival	event|quantity[39]	new|new[39]	coref	11-13[65_0]
8-9	673-677	rate	quantity[39]	new[39]	_	_
8-10	678-680	of	quantity[39]	new[39]	_	_
8-11	681-683	PC	quantity[39]|abstract	new[39]|giv	coref	8-17
8-12	684-686	is	_	_	_	_
8-13	687-691	only	quantity[41]	giv[41]	_	_
8-14	692-693	8	quantity[41]	giv[41]	_	_
8-15	694-695	%	quantity[41]	giv[41]	_	_
8-16	696-699	and	_	_	_	_
8-17	700-702	PC	abstract	giv	coref	9-13
8-18	703-705	is	_	_	_	_
8-19	706-715	projected	_	_	_	_
8-20	716-718	to	_	_	_	_
8-21	719-721	be	_	_	_	_
8-22	722-725	the	abstract[43]	new[43]	_	_
8-23	726-732	second	abstract[43]	new[43]	_	_
8-24	733-740	leading	abstract[43]	new[43]	_	_
8-25	741-746	cause	abstract[43]	new[43]	_	_
8-26	747-749	of	abstract[43]	new[43]	_	_
8-27	750-756	cancer	abstract[43]|abstract|event[45]	new[43]|giv|giv[45]	coref|coref	18-16|18-16
8-28	757-763	deaths	abstract[43]|event[45]	new[43]|giv[45]	_	_
8-29	764-766	by	abstract[43]|event[45]	new[43]|giv[45]	_	_
8-30	767-771	2030	abstract[43]|event[45]|time	new[43]|giv[45]|new	_	_
8-31	772-773	.	_	_	_	_

#Text=Gemcitabine ( Gem ) is approved as a first-line chemotherapeutic drug for PC treatment .
9-1	774-785	Gemcitabine	substance	new	_	_
9-2	786-787	(	_	_	_	_
9-3	788-791	Gem	person	new	coref	10-7[53_0]
9-4	792-793	)	_	_	_	_
9-5	794-796	is	_	_	_	_
9-6	797-805	approved	_	_	_	_
9-7	806-808	as	_	_	_	_
9-8	809-810	a	_	_	_	_
9-9	811-821	first-line	_	_	_	_
9-10	822-838	chemotherapeutic	_	_	_	_
9-11	839-843	drug	_	_	_	_
9-12	844-847	for	_	_	_	_
9-13	848-850	PC	object|event[50]	giv|new[50]	coref|coref|coref|coref	10-9|11-10[64_50]|10-9|11-10[64_50]
9-14	851-860	treatment	event[50]	new[50]	_	_
9-15	861-862	.	_	_	_	_

#Text=However , the response rate of Gem in PC patients is only 12 % and most patients are resistant to Gem within a few weeks .
10-1	863-870	However	_	_	_	_
10-2	871-872	,	_	_	_	_
10-3	873-876	the	quantity[52]	new[52]	coref	10-12[56_52]
10-4	877-885	response	abstract|quantity[52]	new|new[52]	coref	12-37
10-5	886-890	rate	quantity[52]	new[52]	_	_
10-6	891-893	of	quantity[52]	new[52]	_	_
10-7	894-897	Gem	quantity[52]|person[53]	new[52]|giv[53]	coref	10-21[0_53]
10-8	898-900	in	quantity[52]|person[53]	new[52]|giv[53]	_	_
10-9	901-903	PC	quantity[52]|person[53]|abstract|person[55]	new[52]|giv[53]|giv|giv[55]	coref|coref|coref|coref	10-16[57_55]|11-6|10-16[57_55]|11-6
10-10	904-912	patients	quantity[52]|person[53]|person[55]	new[52]|giv[53]|giv[55]	_	_
10-11	913-915	is	_	_	_	_
10-12	916-920	only	quantity[56]	giv[56]	_	_
10-13	921-923	12	quantity[56]	giv[56]	_	_
10-14	924-925	%	quantity[56]	giv[56]	_	_
10-15	926-929	and	_	_	_	_
10-16	930-934	most	person[57]	giv[57]	coref	11-6[62_57]
10-17	935-943	patients	person[57]	giv[57]	_	_
10-18	944-947	are	_	_	_	_
10-19	948-957	resistant	_	_	_	_
10-20	958-960	to	_	_	_	_
10-21	961-964	Gem	substance	giv	coref	11-10
10-22	965-971	within	_	_	_	_
10-23	972-973	a	time[59]	new[59]	_	_
10-24	974-977	few	time[59]	new[59]	_	_
10-25	978-983	weeks	time[59]	new[59]	_	_
10-26	984-985	.	_	_	_	_

#Text=Less than 25 % of PC patients benefit from Gem treatment and the median overall survival is only 6 months .
11-1	986-990	Less	_	_	_	_
11-2	991-995	than	_	_	_	_
11-3	996-998	25	quantity[60]	new[60]	_	_
11-4	999-1000	%	quantity[60]	new[60]	_	_
11-5	1001-1003	of	quantity[60]	new[60]	_	_
11-6	1004-1006	PC	quantity[60]|abstract|person[62]	new[60]|giv|giv[62]	coref|coref|coref|coref	12-31|12-31[77_62]|12-31|12-31[77_62]
11-7	1007-1015	patients	quantity[60]|person[62]	new[60]|giv[62]	_	_
11-8	1016-1023	benefit	_	_	_	_
11-9	1024-1028	from	_	_	_	_
11-10	1029-1032	Gem	substance|event[64]	giv|giv[64]	coref|coref|coref|coref	12-8|21-31[163_64]|12-8|21-31[163_64]
11-11	1033-1042	treatment	event[64]	giv[64]	_	_
11-12	1043-1046	and	_	_	_	_
11-13	1047-1050	the	event[65]	giv[65]	coref	11-18[66_65]
11-14	1051-1057	median	event[65]	giv[65]	_	_
11-15	1058-1065	overall	event[65]	giv[65]	_	_
11-16	1066-1074	survival	event[65]	giv[65]	_	_
11-17	1075-1077	is	_	_	_	_
11-18	1078-1082	only	event[66]	giv[66]	coref	12-40[82_66]
11-19	1083-1084	6	event[66]	giv[66]	_	_
11-20	1085-1091	months	event[66]	giv[66]	_	_
11-21	1092-1093	.	_	_	_	_

#Text=In order to overcome these limitations of Gem , combinatorial regimens such as folinic acid , 5-fluorouracil , irinotecan and oxaliplatin ( FOLFIRINOX ) have been widely used to treat PC patients . FOLFIRINOX presents higher response rates and its median overall survival is nearly 12 months .
12-1	1094-1096	In	_	_	_	_
12-2	1097-1102	order	_	_	_	_
12-3	1103-1105	to	_	_	_	_
12-4	1106-1114	overcome	_	_	_	_
12-5	1115-1120	these	abstract[67]	new[67]	_	_
12-6	1121-1132	limitations	abstract[67]	new[67]	_	_
12-7	1133-1135	of	abstract[67]	new[67]	_	_
12-8	1136-1139	Gem	abstract[67]|substance	new[67]|giv	coref	21-7
12-9	1140-1141	,	_	_	_	_
12-10	1142-1155	combinatorial	abstract[69]	new[69]	_	_
12-11	1156-1164	regimens	abstract[69]	new[69]	_	_
12-12	1165-1169	such	abstract[69]	new[69]	_	_
12-13	1170-1172	as	abstract[69]	new[69]	_	_
12-14	1173-1180	folinic	abstract[69]|place|substance[71]	new[69]|new|new[71]	_	_
12-15	1181-1185	acid	abstract[69]|substance[71]	new[69]|new[71]	_	_
12-16	1186-1187	,	abstract[69]	new[69]	_	_
12-17	1188-1202	5-fluorouracil	abstract[69]|substance	new[69]|new	_	_
12-18	1203-1204	,	abstract[69]	new[69]	_	_
12-19	1205-1215	irinotecan	abstract[69]|substance	new[69]|new	_	_
12-20	1216-1219	and	abstract[69]	new[69]	_	_
12-21	1220-1231	oxaliplatin	abstract[69]|object	new[69]|new	_	_
12-22	1232-1233	(	_	_	_	_
12-23	1234-1244	FOLFIRINOX	substance	new	coref	12-34
12-24	1245-1246	)	_	_	_	_
12-25	1247-1251	have	_	_	_	_
12-26	1252-1256	been	_	_	_	_
12-27	1257-1263	widely	_	_	_	_
12-28	1264-1268	used	_	_	_	_
12-29	1269-1271	to	_	_	_	_
12-30	1272-1277	treat	_	_	_	_
12-31	1278-1280	PC	abstract|person[77]	giv|giv[77]	coref|coref|coref|coref	14-18[0_77]|19-18|14-18[0_77]|19-18
12-32	1281-1289	patients	person[77]	giv[77]	_	_
12-33	1290-1291	.	_	_	_	_
12-34	1292-1302	FOLFIRINOX	abstract	giv	ana	12-40
12-35	1303-1311	presents	_	_	_	_
12-36	1312-1318	higher	abstract[80]	new[80]	_	_
12-37	1319-1327	response	abstract|abstract[80]	giv|new[80]	_	_
12-38	1328-1333	rates	abstract[80]	new[80]	_	_
12-39	1334-1337	and	_	_	_	_
12-40	1338-1341	its	abstract|event[82]	giv|giv[82]	_	_
12-41	1342-1348	median	event[82]	giv[82]	_	_
12-42	1349-1356	overall	event[82]	giv[82]	_	_
12-43	1357-1365	survival	event[82]	giv[82]	_	_
12-44	1366-1368	is	_	_	_	_
12-45	1369-1375	nearly	time[83]	new[83]	_	_
12-46	1376-1378	12	time[83]	new[83]	_	_
12-47	1379-1385	months	time[83]	new[83]	_	_
12-48	1386-1387	.	_	_	_	_

#Text=However , this regimen shows considerable adverse effects such as lower blood counts , fever , infection , diarrhea , and weight loss .
13-1	1388-1395	However	_	_	_	_
13-2	1396-1397	,	_	_	_	_
13-3	1398-1402	this	abstract[84]	new[84]	_	_
13-4	1403-1410	regimen	abstract[84]	new[84]	_	_
13-5	1411-1416	shows	_	_	_	_
13-6	1417-1429	considerable	abstract[86]	new[86]	coref	14-14[96_86]
13-7	1430-1437	adverse	abstract|abstract[86]	new|new[86]	_	_
13-8	1438-1445	effects	abstract[86]	new[86]	_	_
13-9	1446-1450	such	abstract[86]	new[86]	_	_
13-10	1451-1453	as	abstract[86]	new[86]	_	_
13-11	1454-1459	lower	abstract[86]|abstract[88]	new[86]|new[88]	_	_
13-12	1460-1465	blood	abstract[86]|substance|abstract[88]	new[86]|new|new[88]	_	_
13-13	1466-1472	counts	abstract[86]|abstract[88]	new[86]|new[88]	_	_
13-14	1473-1474	,	abstract[86]	new[86]	_	_
13-15	1475-1480	fever	abstract[86]|abstract	new[86]|new	_	_
13-16	1481-1482	,	abstract[86]	new[86]	_	_
13-17	1483-1492	infection	abstract[86]|event	new[86]|new	_	_
13-18	1493-1494	,	abstract[86]	new[86]	_	_
13-19	1495-1503	diarrhea	abstract[86]|abstract	new[86]|new	_	_
13-20	1504-1505	,	abstract[86]	new[86]	_	_
13-21	1506-1509	and	abstract[86]	new[86]	_	_
13-22	1510-1516	weight	abstract[86]|abstract[92]	new[86]|giv[92]	_	_
13-23	1517-1521	loss	abstract[86]|abstract[92]	new[86]|giv[92]	_	_
13-24	1522-1523	.	_	_	_	_

#Text=Therefore , development of new chemotherapeutic drugs that can overcome chemoresistance and have less adverse effects on patients is needed .
14-1	1524-1533	Therefore	_	_	_	_
14-2	1534-1535	,	_	_	_	_
14-3	1536-1547	development	abstract[93]	new[93]	_	_
14-4	1548-1550	of	abstract[93]	new[93]	_	_
14-5	1551-1554	new	abstract[93]|substance[94]	new[93]|new[94]	_	_
14-6	1555-1571	chemotherapeutic	abstract[93]|substance[94]	new[93]|new[94]	_	_
14-7	1572-1577	drugs	abstract[93]|substance[94]	new[93]|new[94]	_	_
14-8	1578-1582	that	_	_	_	_
14-9	1583-1586	can	_	_	_	_
14-10	1587-1595	overcome	_	_	_	_
14-11	1596-1611	chemoresistance	abstract	new	_	_
14-12	1612-1615	and	_	_	_	_
14-13	1616-1620	have	_	_	_	_
14-14	1621-1625	less	abstract[96]	giv[96]	coref	18-8[124_96]
14-15	1626-1633	adverse	abstract[96]	giv[96]	_	_
14-16	1634-1641	effects	abstract[96]	giv[96]	_	_
14-17	1642-1644	on	abstract[96]	giv[96]	_	_
14-18	1645-1653	patients	abstract[96]|person	giv[96]|giv	_	_
14-19	1654-1656	is	_	_	_	_
14-20	1657-1663	needed	_	_	_	_
14-21	1664-1665	.	_	_	_	_

#Text=Oat ( Avena sativa L. ) is an important cereal crop of the family of Poaceae grown worldwide .
15-1	1666-1669	Oat	plant	new	coref	15-8[100_0]
15-2	1670-1671	(	_	_	_	_
15-3	1672-1677	Avena	_	_	_	_
15-4	1678-1684	sativa	_	_	_	_
15-5	1685-1687	L.	_	_	_	_
15-6	1688-1689	)	_	_	_	_
15-7	1690-1692	is	_	_	_	_
15-8	1693-1695	an	plant[100]	giv[100]	_	_
15-9	1696-1705	important	plant[100]	giv[100]	_	_
15-10	1706-1712	cereal	object|plant[100]	new|giv[100]	_	_
15-11	1713-1717	crop	plant[100]	giv[100]	_	_
15-12	1718-1720	of	plant[100]	giv[100]	_	_
15-13	1721-1724	the	plant[100]|abstract[101]	giv[100]|new[101]	_	_
15-14	1725-1731	family	plant[100]|abstract[101]	giv[100]|new[101]	_	_
15-15	1732-1734	of	plant[100]|abstract[101]	giv[100]|new[101]	_	_
15-16	1735-1742	Poaceae	plant[100]|abstract[101]|animal|object[103]	giv[100]|new[101]|new|new[103]	_	_
15-17	1743-1748	grown	plant[100]|abstract[101]|object[103]	giv[100]|new[101]|new[103]	_	_
15-18	1749-1758	worldwide	plant[100]|abstract[101]|object[103]	giv[100]|new[101]|new[103]	_	_
15-19	1759-1760	.	_	_	_	_

#Text=Oats have various advantages ; they require less nutrients to grow than the wheat or the corn .
16-1	1761-1765	Oats	substance	new	_	_
16-2	1766-1770	have	_	_	_	_
16-3	1771-1778	various	abstract[105]	new[105]	ana	16-6[0_105]
16-4	1779-1789	advantages	abstract[105]	new[105]	_	_
16-5	1790-1791	;	_	_	_	_
16-6	1792-1796	they	abstract	giv	_	_
16-7	1797-1804	require	_	_	_	_
16-8	1805-1809	less	substance[107]	new[107]	_	_
16-9	1810-1819	nutrients	substance[107]	new[107]	_	_
16-10	1820-1822	to	_	_	_	_
16-11	1823-1827	grow	_	_	_	_
16-12	1828-1832	than	_	_	_	_
16-13	1833-1836	the	substance[108]	new[108]	_	_
16-14	1837-1842	wheat	substance[108]	new[108]	_	_
16-15	1843-1845	or	_	_	_	_
16-16	1846-1849	the	substance[109]	new[109]	_	_
16-17	1850-1854	corn	substance[109]	new[109]	_	_
16-18	1855-1856	.	_	_	_	_

#Text=Additionally , as people become more aware of their health , more people are consuming oats in the form of oatmeal , granola bars , cookies , and beverages .
17-1	1857-1869	Additionally	_	_	_	_
17-2	1870-1871	,	_	_	_	_
17-3	1872-1874	as	_	_	_	_
17-4	1875-1881	people	person	new	ana	17-9
17-5	1882-1888	become	_	_	_	_
17-6	1889-1893	more	_	_	_	_
17-7	1894-1899	aware	_	_	_	_
17-8	1900-1902	of	_	_	_	_
17-9	1903-1908	their	person|abstract[112]	giv|new[112]	coref|coref|coref|coref	17-12[113_0]|18-9[0_112]|17-12[113_0]|18-9[0_112]
17-10	1909-1915	health	abstract[112]	new[112]	_	_
17-11	1916-1917	,	_	_	_	_
17-12	1918-1922	more	person[113]	giv[113]	_	_
17-13	1923-1929	people	person[113]	giv[113]	_	_
17-14	1930-1933	are	_	_	_	_
17-15	1934-1943	consuming	_	_	_	_
17-16	1944-1948	oats	plant	new	coref	18-6
17-17	1949-1951	in	_	_	_	_
17-18	1952-1955	the	substance[115]	new[115]	_	_
17-19	1956-1960	form	substance[115]	new[115]	_	_
17-20	1961-1963	of	substance[115]	new[115]	_	_
17-21	1964-1971	oatmeal	substance[115]|object	new[115]|new	_	_
17-22	1972-1973	,	substance[115]	new[115]	_	_
17-23	1974-1981	granola	substance[115]|animal|object[118]	new[115]|new|new[118]	_	_
17-24	1982-1986	bars	substance[115]|object[118]	new[115]|new[118]	_	_
17-25	1987-1988	,	substance[115]	new[115]	_	_
17-26	1989-1996	cookies	substance[115]|object	new[115]|new	_	_
17-27	1997-1998	,	substance[115]	new[115]	_	_
17-28	1999-2002	and	substance[115]	new[115]	_	_
17-29	2003-2012	beverages	substance[115]|substance	new[115]|new	_	_
17-30	2013-2014	.	_	_	_	_

#Text=Recent studies have revealed that oats possess beneficial health effects on aging , oxidant , cancer , liver injury , hypercholesterolemia , and gastrointestinal problems .
18-1	2015-2021	Recent	abstract[121]	new[121]	_	_
18-2	2022-2029	studies	abstract[121]	new[121]	_	_
18-3	2030-2034	have	_	_	_	_
18-4	2035-2043	revealed	_	_	_	_
18-5	2044-2048	that	_	_	_	_
18-6	2049-2053	oats	plant	giv	_	_
18-7	2054-2061	possess	_	_	_	_
18-8	2062-2072	beneficial	abstract[124]	giv[124]	coref	19-5[133_124]
18-9	2073-2079	health	abstract|abstract[124]	giv|giv[124]	_	_
18-10	2080-2087	effects	abstract[124]	giv[124]	_	_
18-11	2088-2090	on	abstract[124]	giv[124]	_	_
18-12	2091-2096	aging	abstract[124]|abstract	giv[124]|new	_	_
18-13	2097-2098	,	abstract[124]	giv[124]	_	_
18-14	2099-2106	oxidant	abstract[124]|substance	giv[124]|new	_	_
18-15	2107-2108	,	abstract[124]	giv[124]	_	_
18-16	2109-2115	cancer	abstract[124]|abstract	giv[124]|giv	_	_
18-17	2116-2117	,	abstract[124]	giv[124]	_	_
18-18	2118-2123	liver	abstract[124]|object|abstract[129]	giv[124]|new|new[129]	_	_
18-19	2124-2130	injury	abstract[124]|abstract[129]	giv[124]|new[129]	_	_
18-20	2131-2132	,	abstract[124]	giv[124]	_	_
18-21	2133-2153	hypercholesterolemia	abstract[124]|abstract	giv[124]|new	_	_
18-22	2154-2155	,	abstract[124]	giv[124]	_	_
18-23	2156-2159	and	abstract[124]	giv[124]	_	_
18-24	2160-2176	gastrointestinal	abstract[124]|abstract[131]	giv[124]|giv[131]	_	_
18-25	2177-2185	problems	abstract[124]|abstract[131]	giv[124]|giv[131]	_	_
18-26	2186-2187	.	_	_	_	_

#Text=In this study , the effects of ethanol extract from the oat bran ( OBE ) on PC were investigated in vitro .
19-1	2188-2190	In	_	_	_	_
19-2	2191-2195	this	event[132]	new[132]	_	_
19-3	2196-2201	study	event[132]	new[132]	_	_
19-4	2202-2203	,	_	_	_	_
19-5	2204-2207	the	abstract[133]	giv[133]	_	_
19-6	2208-2215	effects	abstract[133]	giv[133]	_	_
19-7	2216-2218	of	abstract[133]	giv[133]	_	_
19-8	2219-2226	ethanol	abstract[133]|substance|substance[135]	giv[133]|new|new[135]	_	_
19-9	2227-2234	extract	abstract[133]|substance[135]	giv[133]|new[135]	_	_
19-10	2235-2239	from	abstract[133]	giv[133]	_	_
19-11	2240-2243	the	abstract[133]|substance[136]	giv[133]|new[136]	appos	19-15[0_136]
19-12	2244-2247	oat	abstract[133]|substance[136]	giv[133]|new[136]	_	_
19-13	2248-2252	bran	abstract[133]|substance[136]	giv[133]|new[136]	_	_
19-14	2253-2254	(	_	_	_	_
19-15	2255-2258	OBE	substance	giv	coref	20-7[140_0]
19-16	2259-2260	)	_	_	_	_
19-17	2261-2263	on	_	_	_	_
19-18	2264-2266	PC	object	giv	coref	20-9
19-19	2267-2271	were	_	_	_	_
19-20	2272-2284	investigated	_	_	_	_
19-21	2285-2287	in	_	_	_	_
19-22	2288-2293	vitro	_	_	_	_
19-23	2294-2295	.	_	_	_	_

#Text=To confirm the anti-cancer effect of OBE on PC cell viability , colony formation , cell cycle distribution , apoptosis , and proteins were evaluated .
20-1	2296-2298	To	_	_	_	_
20-2	2299-2306	confirm	_	_	_	_
20-3	2307-2310	the	abstract[139]	new[139]	_	_
20-4	2311-2322	anti-cancer	abstract[139]	new[139]	_	_
20-5	2323-2329	effect	abstract[139]	new[139]	_	_
20-6	2330-2332	of	abstract[139]	new[139]	_	_
20-7	2333-2336	OBE	abstract[139]|substance[140]	new[139]|giv[140]	coref	21-9[154_140]
20-8	2337-2339	on	abstract[139]|substance[140]	new[139]|giv[140]	_	_
20-9	2340-2342	PC	abstract[139]|substance[140]|abstract|abstract[143]	new[139]|giv[140]|giv|new[143]	coref|coref	21-11|21-11
20-10	2343-2347	cell	abstract[139]|substance[140]|place|abstract[143]	new[139]|giv[140]|new|new[143]	coref	20-16
20-11	2348-2357	viability	abstract[139]|substance[140]|abstract[143]	new[139]|giv[140]|new[143]	_	_
20-12	2358-2359	,	abstract[139]|substance[140]	new[139]|giv[140]	_	_
20-13	2360-2366	colony	abstract[139]|substance[140]|place|event[145]	new[139]|giv[140]|new|new[145]	_	_
20-14	2367-2376	formation	abstract[139]|substance[140]|event[145]	new[139]|giv[140]|new[145]	_	_
20-15	2377-2378	,	abstract[139]|substance[140]	new[139]|giv[140]	_	_
20-16	2379-2383	cell	abstract[139]|substance[140]|object|abstract[148]	new[139]|giv[140]|giv|new[148]	_	_
20-17	2384-2389	cycle	abstract[139]|substance[140]|object|abstract[148]	new[139]|giv[140]|new|new[148]	_	_
20-18	2390-2402	distribution	abstract[139]|substance[140]|abstract[148]	new[139]|giv[140]|new[148]	_	_
20-19	2403-2404	,	abstract[139]|substance[140]	new[139]|giv[140]	_	_
20-20	2405-2414	apoptosis	abstract[139]|substance[140]|event	new[139]|giv[140]|new	_	_
20-21	2415-2416	,	abstract[139]|substance[140]	new[139]|giv[140]	_	_
20-22	2417-2420	and	abstract[139]|substance[140]	new[139]|giv[140]	_	_
20-23	2421-2429	proteins	abstract[139]|substance[140]|substance	new[139]|giv[140]|new	_	_
20-24	2430-2434	were	_	_	_	_
20-25	2435-2444	evaluated	_	_	_	_
20-26	2445-2446	.	_	_	_	_

#Text=Moreover , the combination effects of Gem and OBE on PC cells with acquired resistance to Gem was investigated to test if combination therapy could overcome drug resistance developed during cancer treatment .
21-1	2447-2455	Moreover	_	_	_	_
21-2	2456-2457	,	_	_	_	_
21-3	2458-2461	the	abstract[152]	new[152]	_	_
21-4	2462-2473	combination	abstract|abstract[152]	new|new[152]	coref	21-23
21-5	2474-2481	effects	abstract[152]	new[152]	_	_
21-6	2482-2484	of	abstract[152]	new[152]	_	_
21-7	2485-2488	Gem	abstract[152]|substance	new[152]|giv	coref	21-17
21-8	2489-2492	and	abstract[152]	new[152]	_	_
21-9	2493-2496	OBE	abstract[152]|substance[154]	new[152]|giv[154]	_	_
21-10	2497-2499	on	abstract[152]|substance[154]	new[152]|giv[154]	_	_
21-11	2500-2502	PC	abstract[152]|substance[154]|substance|object[156]	new[152]|giv[154]|giv|new[156]	_	_
21-12	2503-2508	cells	abstract[152]|substance[154]|object[156]	new[152]|giv[154]|new[156]	_	_
21-13	2509-2513	with	abstract[152]|substance[154]|object[156]	new[152]|giv[154]|new[156]	_	_
21-14	2514-2522	acquired	abstract[152]|substance[154]|object[156]|abstract[157]	new[152]|giv[154]|new[156]|new[157]	coref	21-27[162_157]
21-15	2523-2533	resistance	abstract[152]|substance[154]|object[156]|abstract[157]	new[152]|giv[154]|new[156]|new[157]	_	_
21-16	2534-2536	to	abstract[152]|substance[154]|object[156]|abstract[157]	new[152]|giv[154]|new[156]|new[157]	_	_
21-17	2537-2540	Gem	abstract[152]|substance[154]|object[156]|abstract[157]|substance	new[152]|giv[154]|new[156]|new[157]|giv	_	_
21-18	2541-2544	was	_	_	_	_
21-19	2545-2557	investigated	_	_	_	_
21-20	2558-2560	to	_	_	_	_
21-21	2561-2565	test	_	_	_	_
21-22	2566-2568	if	_	_	_	_
21-23	2569-2580	combination	abstract|abstract[160]	giv|new[160]	_	_
21-24	2581-2588	therapy	abstract[160]	new[160]	_	_
21-25	2589-2594	could	_	_	_	_
21-26	2595-2603	overcome	_	_	_	_
21-27	2604-2608	drug	substance|abstract[162]	new|giv[162]	_	_
21-28	2609-2619	resistance	abstract[162]	giv[162]	_	_
21-29	2620-2629	developed	_	_	_	_
21-30	2630-2636	during	_	_	_	_
21-31	2637-2643	cancer	event[163]	giv[163]	_	_
21-32	2644-2653	treatment	event[163]	giv[163]	_	_
21-33	2654-2655	.	_	_	_	_
